Natus Medical Inc  

(Public, NASDAQ:BABY)   Watch this stock  
Find more results for BABY
36.41
-0.03 (-0.08%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.73 - 36.63
52 week 23.40 - 42.96
Open 36.40
Vol / Avg. 235,463.00/238,749.00
Mkt cap 1.21B
P/E 34.90
Div/yield     -
EPS 1.04
Shares 32.96M
Beta 0.79
Inst. own 89%
Jul 21, 2015
Q2 2015 Natus Medical Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 1, 2015
Natus Medical Inc at Jefferies Global Healthcare Conference - 8:30AM EDT - Add to calendar
Jun 1, 2015
Natus Medical Incorporated Annual Shareholder Meeting (Estimated) Add to calendar
Apr 22, 2015
Q1 2015 Natus Medical Inc Earnings Call - Webcast
Apr 22, 2015
Q1 2015 Natus Medical Inc Earnings Release
Mar 9, 2015
Natus Medical Inc at ROTH Conference
Mar 2, 2015
Natus Medical Inc at Raymond James Institutional Investors Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 9.62% 9.13%
Operating margin 14.93% 12.89%
EBITD margin - 17.48%
Return on average assets 7.85% 7.52%
Return on average equity 9.70% 9.83%
Employees 948 -
CDP Score - -

Address

6701 Koll Center Pkwy Ste 120
PLEASANTON, CA 94566-8061
United States - Map
+1-925-2236700 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Natus Medical Incorporated is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The Company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. Natus categorizes its products into two categories: neurology and newborn care.

Officers and directors

Robert A. Gunst Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James B. Hawkins President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jonathan A. Kennedy Chief Financial Officer, Senior Vice President
Age: 44
Bio & Compensation  - Reuters
Austin F. Noll III Vice President and General Manager - Neurology Strategic Business Unit
Age: 48
Bio & Compensation  - Reuters
Kenneth M. Traverso Vice President, General Manager - Newborn Care Strategic Business Unit
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ajay A. Bhave Vice President - Global Engineering
Age: 58
Bio & Compensation  - Reuters
D. Christopher Chung M.D. Vice President - Medical Affairs, Quality & Regulatory
Age: 51
Bio & Compensation  - Reuters
Doris E. Engibous Independent Director
Age: 60
Bio & Compensation  - Reuters
Kenneth E. Ludlum Independent Director
Age: 61
Bio & Compensation  - Reuters
Will M. Moore Jr. Independent Director
Age: 66
Bio & Compensation  - Reuters